Alpha-lipoic acid (ALA) is a compound produced naturally in small amounts by the body and found in trace amounts in foods like spinach and broccoli. It’s also sold in supplement form. Unlike many supplements in the blood sugar space, it has a reasonably solid research foundation — though it’s often overstated.

Here’s what the evidence actually shows.

What ALA is and how it works

ALA is a cofactor for several mitochondrial enzymes involved in energy metabolism. It’s also a potent antioxidant — both fat-soluble and water-soluble, which makes it unusual (most antioxidants are one or the other). It can regenerate other antioxidants, including vitamin C and vitamin E.

For blood sugar, the main mechanism of interest is GLUT4 translocation. GLUT4 is the glucose transporter that moves glucose from the bloodstream into muscle and fat cells — it’s one of the primary means by which insulin clears blood glucose. ALA appears to activate pathways (particularly AMPK and PI3K) that cause GLUT4 to move to the cell surface, independent of insulin. This is the same type of pathway activated by exercise.

In theory, this means ALA could improve glucose uptake and insulin sensitivity through an insulin-independent mechanism — useful in people whose cells are insulin resistant.

What the research shows for blood sugar

A 2011 meta-analysis in Obesity Reviews looked at five randomized controlled trials on ALA supplementation and insulin resistance. The conclusion: ALA at 600–1,200 mg per day for 4–24 weeks produced modest but statistically significant reductions in fasting blood glucose and improvements in insulin sensitivity.

A 2018 meta-analysis in Pharmacological Research pooled data from multiple trials and found ALA supplementation significantly reduced fasting blood glucose (by about 6 mg/dL on average) and insulin resistance markers. The effects were more pronounced in people with higher baseline glucose levels.

These are modest effects — not dramatic. ALA is not a first-line intervention for significant blood sugar problems, and the studies are generally smaller and shorter-term than would be ideal.

Where the evidence is stronger: diabetic neuropathy

ALA has been researched more extensively — and with more consistent results — for diabetic peripheral neuropathy than for blood sugar specifically.

In Europe, ALA is approved as a medical treatment for diabetic neuropathy. The ALADIN and SYDNEY trials found that intravenous ALA improved neuropathy symptoms (burning, pain, numbness) significantly. The oral form has also shown benefits in several trials, though the effect is smaller.

A 2004 meta-analysis in Diabetic Medicine found that oral ALA at 600 mg per day for five weeks produced significant symptom improvement in people with peripheral neuropathy.

Safety and dosing

Oral ALA at 300–600 mg per day is the most common dose in metabolic studies. Higher doses (up to 1,200 mg) have been used without significant adverse effects in clinical trials.

The main caution is potential interaction with thyroid medications — ALA can reduce the absorption of levothyroxine, so spacing doses apart is recommended if you’re on thyroid medication. Some animal studies at very high doses raised concerns about thiamine deficiency, but this has not been reproduced in human trials at standard doses.

For people managing blood sugar or with early neuropathy symptoms, ALA is one of the more evidence-supported supplements available. It’s not transformative, but the evidence for a modest benefit is consistent.


This content is for educational purposes only and is not medical advice. Consult your healthcare provider before making changes to your diet, supplements, or medications.